Revolution Medicines IPO

2/12/2020

IPO

$238,000,000

Approximately $150 million to $175 million to fund the development of our multiple RAS programs, including our RAS(ON) portfolio and SOS1 program, through completion of IND-enabling studies for one or more development candidates and initiation of a Phase 1 clinical trial for one development candidate; Approximately $25 million to $30 million to fund the development of our 4EBP1/mTORC1 program through initiation of a Phase 1 clinical trial for RMC-5552; Approximately $1 million, net of reimbursement from Sanofi, to fund our share of research costs for the SHP2 program; and The remaining proceeds for other general corporate purposes, which may include the hiring of additional personnel, capital expenditures and the costs of operating as a public company.

Publicly-held

Biopharmaceutical

700 Saginaw Dr.
Redwood City, CA 94063
USA

Revolution Medicines (Nasdaq: RVMD) discovers and develops important new medicines for cancer patients by translating frontier oncology targets--proteins that drive the growth of cancers or that control immune responses that can defeat them.